

# MITOCHONDRIAL AND INHERITED METABOLIC DISEASES TASK FORCE WITH CRITICAL PATH INSTITUTE (C-PATH)

## About C-Path



press release

C-Path's Rare Diseases Cures Accelerator – Data Analytics Platform (RDCA-DAP®) is an FDA-funded initiative establishing a centralized and standardized infrastructure. This platform facilitates the sharing of crucial data across rare diseases, enabling integration and standardization of diverse data types, e.g., registry, trials, etc.

### Mission

Standardizing and integrating mitochondrial and inherited metabolic diseases data into the **RDCA-DAP®**.

Optimizing clinical trial design and endpoints.

Enhancing communication and collaboration among stakeholders, and the medical and research communities at large, all aimed at **improving the lives of those affected by these diseases.**

### Why share data?

By participating or sharing data with C-Path your data is entrusted to a **neutral entity** with **expertise in data governance**, sharing, proper **data aggregation and analytics**, and **working with regulatory bodies**.

**Data contributors** decide how their data is shared and used.

All of this together has the **maximum chance** of benefiting as many **people living with mitochondrial and metabolic diseases** as possible.

## Members

Astellas Pharma Inc.  
Barth Syndrome Foundation  
CortexBio  
Cure ARS  
Cure LBSL Foundation  
Cure Mito Foundation  
Global Genes: Rare-X Platform  
Hope for PDCD  
LHON Collective  
Lily Foundation

Mepan Foundation  
MitoAction  
MitoCanada  
Mitochondria World  
Midwestern Washington University  
National Institutes of Health  
Sanford Research  
TGEN  
The Champ Foundation  
Newcastle upon Tyne  
Washington University at St. Louis